Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 12.51B P/E 6.64 EPS this Y -8.90% Ern Qtrly Grth -
Income -646.5M Forward P/E 3.65 EPS next Y 0.70% 50D Avg Chg 6.00%
Sales 15.24B PEG -1.36 EPS past 5Y -11.64% 200D Avg Chg -
Dividend 5.00% Price/Book 0.60 EPS next 5Y -3.20% 52W High Chg -16.00%
Recommedations 2.60 Quick Ratio 0.65 Shares Outstanding 1.19B 52W Low Chg 24.00%
Insider Own 0.32% ROA 2.54% Shares Float 1.19B Beta 0.93
Inst Own 84.37% ROE -3.20% Shares Shorted/Prior 35.63M/35.56M Price 10.43
Gross Margin 42.32% Profit Margin -4.24% Avg. Volume 9,555,456 Target Price 15.52
Oper. Margin 9.50% Earnings Date Nov 7 Volume 8,361,564 Change 2.05%
About Viatris Inc.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc. News
11/13/24 Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
11/11/24 ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
11/08/24 Viatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...
11/07/24 S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate
11/07/24 Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance
11/07/24 Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
11/07/24 Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates
11/07/24 Viatris: Q3 Earnings Snapshot
11/07/24 Viatris Reports Third Quarter Financial Results for 2024
11/05/24 What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
11/05/24 Viatris Announces Third Quarter 2024 Dividend
11/04/24 Viatris to Report Q3 Earnings: What's in the Cards?
11/04/24 Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics
10/29/24 Viatris Named to Forbes' World's Top Companies for Women 2024 List
10/29/24 Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference
10/17/24 Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe
10/17/24 Lexicon partners Viatris for global expansion of sotagliflozin
10/16/24 Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
10/16/24 Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
10/16/24 Strength Seen in Cencora (COR): Can Its 3.7% Jump Turn into More Strength?
VTRS Chatroom

User Image JordynObrien Posted - 21 hours ago

$INCY $VTRS LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image HarveyToronto Posted - 23 hours ago

$VTRS just wanted to leave this here for future. look at the gross margin, Free Cash flow and Net debt. All are improving. VTRS is trading at forward p/e 4.9 which is very cheap compare to improving fundamentals.

User Image JusticeApple Posted - 23 hours ago

[ $INCY $VTRS] LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image smartkarma Posted - 1 day ago

$VTRS | Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth! - Major Drivers "Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position. Notably, the company delivered..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/viatris-inc-expansion-of-innovative-portfolio-as-a-vital-factor-driving-growth-major-drivers

User Image ShirleyG Posted - 1 day ago

$VTRS wow🔥 $15🚀always

User Image Chortlemethis Posted - 2 days ago

$VTRS In one of my portfilios, this has grown to #3 (about to move in to #2) as it has steadily improved its financial and operating situation. I see many bright years ahead.

User Image NVDAMillionaire Posted - 3 days ago

$VTRS Viatris Inc. (VTRS): Navigating Through Transformative Changes and Building a Durable Future https://beyondspx.com/article/viatris-inc-nasdaq-vtrs-bridging-the-divide-between-generics-and-brands

User Image TalkMarkets Posted - 4 days ago

3 Chart Patterns That Cut Through The Market’s Chaos $DOCS $TMHC $VTRS https://talkmarkets.com/content/stocks--equities/3-chart-patterns-that-cut-through-the-markets-chaos?post=469432

User Image 11thestate Posted - 5 days ago

$VTRS agreed to settle $16M with investors to end claims over the misrepresentations in the Mylan merger case. Even if the deadline has passed, if you bought between 2020 and 2022, you can still file for payment here: https://11thestate.com/cases/viatris-investor-settlement

User Image diegomontana Posted - 5 days ago

$VTRS Idorsia ia facing bankruptcy. This is what WS is telling us (CHf 0,80 per share). What will Happen with the deal they made ?

User Image Doc62 Posted - 5 days ago

$LXRX America is getting fatter Lexicon has been active, recently participating in Obesity Week in SA This week in Chicago presenting at the American Heart Association's Sessions Next week participating at the Jefferies London Global Healthcare Conference which will be available by webcast Doing their work. Partnering with Viatris IMO is bullish as Fvck... OBVIOUSLY $VTRS would love to swoop into the US and European markets https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01548-4/fulltext

User Image ItsCarRamRod Posted - 6 days ago

$VTRS Still filling the gap back to 11

User Image crett Posted - 1 week ago

$VTRS

User Image ItsCarRamRod Posted - 1 week ago

$VTRS you had to know the gains wouldn't last.

User Image ChristaBoarts Posted - 1 week ago

$VTRS IBO’s expertise in enhanced phenolic compounds is setting up solid growth potential.

User Image KCclean Posted - 1 week ago

$VTRS starter on smol dip today

User Image ItsCarRamRod Posted - 1 week ago

$VTRS big gap to fill back to $11

User Image 11thestate Posted - 1 week ago

$VTRS agreed to settle $16M with investors to end claims over the misrepresentations in the Mylan merger case. Even if the deadline has passed, if you bought between 2020 and 2022, you can still file for payment here: https://11thestate.com/cases/viatris-investor-settlement

User Image ahab Posted - 1 week ago

$VTRS gambit

User Image EarningsCallSamurAI Posted - 1 week ago

$VTRS Financial Highlights From Last Earnings Call • Total revenues of $3.8 billion, representing operational revenue growth of approximately 3%. • Adjusted EBITDA of $1.3 billion, growing approximately 4% year-over-year. • Adjusted EPS of $0.75 per share, growing approximately 6% year-over-year. • Free cash flow generated of $866 million, excluding transaction costs and taxes. • New product revenues of $133 million for the quarter. • Repayment of approximately $1.9 billion in debt, achieving long-term gross leverage target. Check the full report, link in bio!

User Image CunningStunt69 Posted - 1 week ago

$VTRS if this doesn’t run into the end of the year I’ll be adding. Couldn’t have asked for much more, I don’t see why it shouldn’t be $20+ a share.

User Image BEARHODL Posted - 1 week ago

$VTRS $45 at least before eoy I will be happy

User Image BEARHODL Posted - 1 week ago

$VTRS +$20 next

User Image ShirleyG Posted - 1 week ago

$VTRS woot woot🔥🚀🚀🚀🚀 always

User Image Investor54321 Posted - 1 week ago

@T7Boeing I'm a big fan of $VTRS but the FCF is $1.6B not 4B. https://investor.viatris.com/news-releases/news-release-details/viatris-reports-third-quarter-financial-results-2024

User Image StockWriter69 Posted - 1 week ago

@MS_Tammy any thoughts on $VTRS and todays earnings report?

User Image Investor54321 Posted - 1 week ago

@T7Boeing I'm a big fan of $VTRS but this statement is not true. They have not announced a future buyback

User Image Investor54321 Posted - 1 week ago

@T7Boeing I'm a big fan of $VTRS as well, but this is not true. It's #10 https://whalewisdom.com/filer/greenlight-capital-inc#google_vignette

User Image Chortlemethis Posted - 1 week ago

$VTRS I DCAd for a long time and happy to see it finally paying off.

User Image MrNotSoNice Posted - 1 week ago

$VTRS This has been low for a long time while $TEVA is a flyer. Viatris will have its day. 🧐📈💵💊

Analyst Ratings
Piper Sandler Neutral Mar 28, 24
Piper Sandler Neutral Nov 22, 23
B of A Securities Underperform Oct 23, 23
Barclays Underweight Jun 23, 23
Barclays Equal-Weight Apr 25, 23
Barclays Equal-Weight Apr 24, 23
Barclays Overweight Feb 28, 23
BMO Capital Market Perform Feb 17, 23
Barclays Overweight Feb 1, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Cuneo Andrew See Remarks See Remarks Jan 04 Sell 11.50 4,000 46,000 42,795 01/05/24
Cuneo Andrew See Remarks See Remarks Dec 14 Sell 10.50 4,000 42,000 46,795 12/15/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Nov 23 Sell 9.37 14,937 139,960 64,658 11/24/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Nov 23 Option 0 33,179 79,595 11/24/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Mar 02 Sell 11.13 6,241 69,462 46,416 03/06/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Mar 02 Option 0 15,600 49,564 03/06/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Feb 27 Sell 11.22 5,250 58,905 37,057 03/01/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Feb 27 Option 0 13,142 42,307 03/01/23
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Nov 23 Option 0 31,644 41,965 11/25/22
Ni Xiangyang (Sean) President, Greater C.. President, Greater China Nov 23 Sell 10.95 12,800 140,160 29,165 11/25/22
van der Meer Mohr Pauline Director Director Aug 17 Sell 10.5839 9,440 99,912 20,543 08/19/22
Taddese Menassie See Remarks See Remarks May 27 Sell 12.0737 8,813 106,406 05/27/22
READ IAN C Director Director Mar 21 Option 0.00 166 14,497 03/23/22
PARRISH MARK W Director Director Mar 21 Option 0.00 166 82,250 03/23/22
MARK RICHARD A Director Director Mar 21 Option 0.00 166 33,165 03/23/22
Lyons Dillon JoEllen Director Director Mar 21 Option 0.00 166 39,546 03/23/22
DIMICK NEIL F Director Director Mar 21 Option 0.00 166 75,200 03/23/22
KORMAN HARRY Director Director Mar 21 Option 0.00 166 50,638 03/23/22
KILTS JAMES M Director Director Mar 21 Option 0.00 166 79,402 03/23/22
HIGGINS MELINA E Director Director Mar 21 Option 0.00 166 63,068 03/23/22
CORNWELL W DON Director Director Mar 21 Option 0.00 166 22,197 03/23/22
CORNWELL W DON Director Director Mar 15 Buy 9.8968 2,700 26,721 22,031 03/15/22
GOETTLER MICHAEL Chief Executive Offi.. Chief Executive Officer Mar 15 Buy 9.866 50,352 496,773 136,796 03/15/22
COURY ROBERT J Executive Chairman Executive Chairman Mar 09 Sell 10.17 500,000 5,085,000 03/11/22